Polymer-grafted starch microparticles for oral and nasal immunization

Immunology and Cell Biology

Volumn 76, Issue 3, 1998, Pages 256-262

  McDermott, Mark R ^a   Heritage, Philippa L ^a   Bartzoka, Vasiliki ^b   Brook, Michael A ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Immunization; Microparticles; Nasal; Oral; Starch

Indexed keywords

ANTIGEN; POLYMER; STARCH;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; IMMUNIZATION; IMMUNOGENICITY; INTRANASAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; MICROSPHERES; POLYMERS; STARCH; VACCINATION;

EID: 0031842330     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00743.x     Document Type: Article

References (52)

1. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system: I. Migration of B immunoblasts into intestinal, respiratory and genital tissues. J. Immunol. 1979; 122: 1892-8.
2. Croituru K, Bienenstock J. Characteristics and functions of mucosa-associated lymphoid tissue. In: Orgra PI, Mestecky J, Lamm J, Strober W, McGhee JR, Bienenstock J (eds) Handbook of Mucosal Immunology. New York: Academic Press, 1994; 141-9.
3. McDermott MR, Heritage PL, Loomes LM, Rosenthal KC, Underdown BJ. Potential for vaccination against sexually transmitted diseases. In: Broson RA, Alexander NJ, Anderson D, Branch DW, Katteh WH (eds) Reproductive Immunology. Oxford: Blackwell Science, 1996; 585-610.
4. Mestecky J, Abraham R, Orgra PL. Common mucosal immune system and strategies for the development of vaccines effective at mucosal surfaces. In: Orgra PL, Mestecky J, Lamm M, Strober W, McGhee JR, Bienenstock J (eds) Handbook of Mucosal Immunology. New York: Academic Press, 1994; 357-72.
5. Georgescu MM, Balavant J, Macadam A et al. Evolution of the sabin type 1 poliovirus in humans: Characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 1997; 71: 7758-68.
6. Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Mestecky J, Orgra PL, Lamm ME, Strober W, McGhee JR, Bienenstock J (eds) Handbook of Mucosal Immunology. New York: Academic Press, 1994; 391-402.
7. Jackson S, Mestecky J, Childers NK, Michalek SM. Liposomes containing anti-idiotypic antibodies: An oral vaccine to induce protective secretory immune responses specific for pathogens of mucosal surfaces. Infect. Immun. 1990; 58: 1932-6.
8. Guzman CA, Molinari G, Fountain MW, Rohide M, Timmis KN, Walker MJ. Antibody responses in serum and respiratory tract following oral immunization with liposomes coated with filamentous hemagglutinin and pertussis toxoid. Infect. Immun. 1993; 61: 573-9.
9. Mowat AM, Maloy KJ, Donachie AM. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 1993; 80: 527-34.
10. Mannino RJ, Gould-Fogerite S. Lipid matrix-based vaccines for mucosal and systemic immunization. Pharm. Biotechnol. 1995; 6: 363-87.
11. Lowell GH. Proteosomes for improved nasal, oral or injectable vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS (eds) New Generation Vaccines. New York: Marcel Dekker Inc., 1997; 193-207.
12. O'Hagan DT, Rafferty D, Wharton S, Ilium L. Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine 1993; 11: 660-4.
13. Klipstein FA, Engert RF, Sherman WT. Peroral immunization of rats with Escherichia coli heat-labile enterotoxin delivered by microspheres. Infect. Immun. 1983; 39: 1000-3.
14. Almeida AJ, Alpar HO, Brown MR. Immune response to nasal delivery of anigenically intact tetanus toxoid associated with poly (L-lactic acid) microspheres in rats, rabbits and guinea-pigs. J. Pharm. Pharmacol. 1993; 45: 198-203.
15. Challacombe SJ, Rahman D, Jeffery H, Davis SS, O'Hagan DT. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 1992; 76: 164-8.
16. Eldridge JH, Gilley RM, Staas JK, Moldoveanu Z, Meulbroek JA, Tice TR. Biodegradable microspheres: Vaccine delivery system for oral immunization. Curr. Top. Microbiol. Immunol. 1989; 146: 59-66.
17. O'Hagan DT, McGhee JP, Holmgren J et al. Biodegradable microspheres for oral immunization. Vaccine 1993; 11: 149-54.
18. Allaoui-Attarki K, Pacquet S, Fattal E et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (DL-lactide-co-glycolide) microspheres. Infect. Immun. 1997; 65: 853-7.
19. Shahin R, Leef M, Eldridge J, Hudson M, Galley R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly (DL-lactide-co-glycolide) microspheres. Infect. Immun. 1995; 63: 1195-200.
20. Edelman R, Russell RG, Losonsky G et al. Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/1) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide). Vaccine 1993; 11: 155-8.
21. Ray R, Novak M, Duncan JD, Matsuoka Y, Compans RW. Microencapsulated human parainfluenza virus induces a protective immune response. J. Infect. Dis 1993; 167: 752-5.
22. Marx PA, Compans RW, Geettie A et al. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993; 260: 1323-7.
23. Jain SL, Barone KS, Flanagan MP, Michael JG. Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen. Vaccine 1996; 14: 1291-7.
24. Offit PA, Khoury CA, Moser CA, Clark HF, Kim JE, Speaker TJ. Enhancement of rotavirus immunogenicity by microencapsulation. Virology 1994; 203: 134-43.
25. Heritage PL, Loomes LM, Jianxiong J, Brook MA, Underdown BJ, McDermott MR, Novel polymer-grafted starch microparticles for mucosal delivery of vaccines. Immunology 1996; 88: 162-8.
26. Heritage PL, Brook MA, Underdown BJ, McDermott MR. Intranasal immunization with polymer-grafted microparticles acivates the nasal-associated lymphoid tissue and draining lymph nodes. Immunology 1998 (in press).
27. Haas S, Miura-Fraboni J, Zavala F, Kenichiro M, Leone-Bay A, Santiago N. Oral immunization with a model protein entrapped in microspheres prepared from derivatized alpha-amino acids. Vaccine 1996; 14: 785-91.
28. Payne LG, Jenkins SA, Andrianov A, Roberts BE. Water soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm. Biotechnol. 1995; 6: 473-93.
29. Mora M, Pato J. Preparation of egg albumin microparticles for oral application. J. Control Rel. 1993; 25: 107-13.
30. Jepson MA, Clark MA, Foster N et al. Targeting to intestinal M cells. J. Anat. 1996; 189: 507-16.
31. Moldoveanu Z, Novak M, Huang W-Q et al. Oral immunization with influenza in biodegradable microspheres. J. Infect. Dis. 1993; 167: 84-90.
32. Smith MW, Thomas NW, Kenkins PG, Miller NG, Cremashin D, Porta C. Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats. Exp. Physiol. 1995; 80: 735-43.
33. Krey A, Giannasca KT, Weltzein R et al. Role of the glycocolyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: Implications for microbial attachment and oral vaccine targeting. J. Exp. Med. 1996; 184: 1045-59.
34. LeFevre ME, Joel DD, Schidlovsky G. Retention of ingested latex particles in Peyer's patches of germfree and conventional mice. Proc. Soc. Exp. Biol. Med. 1985; 179: 522-8.
35. Jani P, Halbert GW, Langridge J, Florence AP. The uptake and translocation of latex nanoparticles and microspheres after oral administration to rats. J. Pharm. Pharmacol. 1989; 41: 809-12.
36. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly (DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 1991; 59: 2978-86.
37. O'Hagan DT, Jeffery H, Roberts MJ, McGhee JP, Davis SS. Controlled release microparticles for vaccine development. Vaccine 1991; 9: 768-71.
38. Tacket CO, Reid RH, Boedeker EC et al. Enteral immunization and challenge of volunteers given enterotoxogenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine 1994; 12: 1270-4.
39. Whistler RL, Bemiller JN, Paschall EF. Starch: Chemistry and Technology, 2nd edn. Orlando: Academic Press, 1984.
40. Laccourreye O, Laurent A, Polivka M et al. Biodegradable starch microspheres for cerebral arterial embolization. Invest. Radiol. 1993; 28: 150-4.
41. Owen MJ. Surface chemistry and applications. In: Clarkson S, Semlyen JA (eds) Siloxane Polymers. Engelwood Cliffs, New Jersey: Prentice-Hall, 1993; 309-72.
42. The United States Pharmacopoeialn Convention Inc. The United States Pharmacopoeia. New York: Rand McNally, Taunton, 1994.
43. Speier JL. Homogeneous catalysis of hydrosilation by transition metals. Adv. Organomet. Chem. 1979; 17: 407-29.
44. Ojima I. The Hydrosilylation Reaction. In: Patai S, Rappoport Z (eds) The Chemistry of Organic Silicon Compounds. Chichester: Wiley. 1989: 1479-526.
45. Brook MA, Bartzoka V, McDermott MR. Protein silicone interactions: How compatible are the two species? Langmuir (in press).
46. Brook MA, Bartzoka V, McDermott MR. Silicon-protein films: Establishing the strength of the protein-silicone interaction. Langmuir (in press).
47. Brook MA, Jiang J, Heritage P, Bartzoka V, Underdown B, McDermott MR. Silicon-protein interaction at the interface between a functional silicone and a protein/starch microparticle. Colloids and Surfaces B: Biointerfaces 1997; 9: 285-95.
48. Brook MA, Jiang J, Heritage P,. Underdown B, McDermott MR. The silicone-protein interaction at the interface between a functional silicone and a protein starch microparticle. Langmuir 1997; 13: 6279-86.
49. Heritage PL, Underdown BJ, Brook MA, McDermott MR. Oral administration of polymer-grafted starch microparticles activates gut-associated lymphocytes and primes mice for subsequent systemic antigen challenge. Vaccine 1998 (in press).
50. Butler JE, Lu EP, Navarro P, Christiansen B. The absorption of proteins on a polydimethylsiloxane edastomer (PEP) and their antigenic behaviours. In: Potler M, Rose NR (eds) Immunology of Silicons. Berlin: Springer-Verlag, 1996; 75-84.
51. Heritage PL, Underdown BJ, Arsenault AL, Snider DP, McDermott MR. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am. J. Respir. Crit. Care Med. 1997; 156: 1256-62.
52. Weiner HL. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol. Today 1997; 18: 335-43.